Is imatinib a chemotherapy drug or a targeted drug?

Imatinib (Imatinib) is a targeted drug rather than a traditional chemotherapy drug. It is a tyrosine kinase inhibitor (Tyrosine Kinase Inhibitor, TKI) that specifically targets specific molecular signaling pathways in certain cancer cells. It is significantly different from traditional chemotherapy drugs in terms of mechanism of action and side effects.

The principle of traditional chemotherapy drugs is to kill cancer cells by attacking rapidly dividing cells. However, this method is not selective and can also cause damage to normal cells, especially rapidly dividing cells such as bone marrow, digestive tract and hair. As a result, chemotherapy drugs are often accompanied by a series of serious side effects, such as nausea, vomiting, hair loss, anemia, and decreased immune function. As a targeted drug, imatinib mainly acts on specific abnormal molecules in cancer cells, so it has fewer side effects and less damage to normal cells.

Imatinib's targeting mechanism focuses on the BCR-ABL fusion protein, which is caused by the translocation of chromosomes 9 and 22 in patients with chronic myelogenous leukemia (CML). This fusion protein has abnormal tyrosine kinase activity and continues to promote the proliferation of leukemia cells. Imatinib controls the growth and spread of leukemia cells by specifically inhibiting the activity of BCR-ABL tyrosine kinase and preventing it from transmitting proliferation signals. Imatinib not only shows significant efficacy in CML, but also plays an important role in gastrointestinal stromal tumors (GIST), a type of tumor Often accompanied by KIT or PDGFRA gene mutations, imatinib inhibits the growth of tumor cells by inhibiting the kinase activity of these genes.

Another major difference between imatinib and chemotherapy drugs is the persistence of treatment goals. For CML patients, imatinib usually needs to be taken for a long time to help patients control the disease in the long term and make it chronic. Chemotherapy is mostly concentrated in the short term, with the goal of quickly reducing the number of cancer cells.

In short, imatinib is a targeted drug. By targeting specific molecular targets, it brings a more selective cancer treatment method than traditional chemotherapy, reduces the incidence of side effects, and significantly improves the quality of life of some cancer patients.